Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02371291
Other study ID # Mrccbu
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received February 9, 2015
Last updated September 7, 2017
Start date January 2015
Est. completion date January 2017

Study information

Verified date September 2017
Source Medical Research Council Cognition and Brain Sciences Unit
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Our collection of memories for personal experiences plays an important role in shaping our sense of who we are as people. These memories, termed autobiographical memories, can also be helpful in social situations, for sharing the details of our experiences with other people, reminiscing about pleasant times and solving problems by remembering what has and hasn't worked in the past. Different types of autobiographical memory are helpful to us depending on the particular situation the investigators are in at the time. Recent research has shown that experiencing depressed mood can affect how we relate to our autobiographical memories, so that instead of providing a rich source of personal information in a helpful and flexible way, the types of memories that come to mind are more narrowly focused on difficult or negative experiences. This can cause low mood to persist over time.

The purpose of this study is to test a newly-developed therapeutic training package for depressed mood (MemFlex), designed to encourage helpful and flexible ways of relating to autobiographical memories. The MemFlex programme consists of a one-to-one orientation session with the researcher to introduce the training package, followed by a workbook that is completed at home.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Currently experiencing Major Depressive Episode, indexed on the Structured Clinical Interview for the DSM-IV (SCID; First et al., 1996).

- Score of 13 or above on the Beck Depression Inventory (Beck et al., 1996)

Exclusion Criteria:

- SCID assessment indicates they are experiencing another mood disorder, psychosis, current alcohol or substance dependence/abuse.

- Diagnosed Axis II disorder or brain injury (assessed by participant report)

Study Design


Intervention

Behavioral:
Memory Flexibility Training
As in experimental arm description.
Psychoeducation
As in experimental arm description.

Locations

Country Name City State
United Kingdom Cambridge and Peterborough NHS Foundation Trust Cambridge
United Kingdom MRC Cognition and Brain Sciences Unit Cambridge

Sponsors (1)

Lead Sponsor Collaborator
Medical Research Council Cognition and Brain Sciences Unit

Country where clinical trial is conducted

United Kingdom, 

References & Publications (4)

Beck, A., Steer, R., & Brown, G. (1996). Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.

Dalgleish T, Bevan A, McKinnon A, Breakwell L, Mueller V, Chadwick I, Schweizer S, Hitchcock C, Watson P, Raes F, Jobson L, Werner-Seidler A. A comparison of MEmory Specificity Training (MEST) to education and support (ES) in the treatment of recurrent depression: study protocol for a cluster randomised controlled trial. Trials. 2014 Jul 22;15:293. doi: 10.1186/1745-6215-15-293. — View Citation

First, M., Spitzer, R., Gibbons, M., & Williams, J. (1996). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV). Washington, DC: American Psychiatric Press.

Raes F, Williams JM, Hermans D. Reducing cognitive vulnerability to depression: a preliminary investigation of MEmory Specificity Training (MEST) in inpatients with depressive symptomatology. J Behav Ther Exp Psychiatry. 2009 Mar;40(1):24-38. doi: 10.1016/j.jbtep.2008.03.001. Epub 2008 Mar 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change in Rumination as measured by Rumination Response Scale Rumination Response Scale (Treynor, Gonzalez, Nolen-Hoeksema, 2003); 4-6 weeks after beginning the workbook
Other Change in Cognitive Avoidance, as measured by Cognitive Avoidance Questionnaire Cognitive Avoidance Questionnaire (Sexton & Dugas, 2008) 4-6 weeks after beginning the workbook
Other Change in Verbal Fluency as measured by the Verbal Fluency Task Verbal Fluency Task 4-6 weeks after beginning the workbook
Other Change in Anxiety symptoms, as measured by the Beck Anxiety Inventory Beck Anxiety Inventory 4-6 weeks after beginning the workbook
Other Change in Hopelessness, as measured by Beck Hopelessness Scale Beck Hopelessness Scale 4-6 weeks after beginning the workbook
Other Change in Problem solving, as measured by the Means-Ends Problem Solving task Means-Ends Problem Solving task (Lyubomirsky & Nolen-Hoeksema, 2003) 4-6 weeks after beginning the workbook
Primary Depressive Status Three months after completion of the workbook
Primary Change in score on the Beck Depression Inventory (Beck, Steer, & Brown, 1996) from baseline Self report measure of depression symptoms Three months after completion of the workbook
Secondary Depression free days Number of depression free days from post to follow-up. Three months after completion of the workbook
Secondary Change in memory flexibility from baseline, Score on the alternating instructions autobiographical memory task (Dritschel et al., 2013) Score on the alternating instructions autobiographical memory task (Dritschel et al., 2013) Three months after completion of the workbook
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A